Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients

  • A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral pill for high-risk patients.
  • The expert panel conditionally recommended molnupiravir for patients with non-severe disease at high risk of hospitalization, such as the immunocompromised, the unvaccinated, older people, and those with chronic conditions.
  • The recommendation was based on new data from six clinical trials involving 4,796 patients.
  • Related: See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization.
  • Since molnupiravir's U.S. authorization in December, demand for the pill among COVID-19 patients has taken a hit from comparatively low efficacy.
  • The panel also updated its guidance for the use of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) casirivimab-imdevimab COVID-19 antibody cocktail. 
  • It now recommends the drug only for people who are not infected with omicron as new data has shown it is not effective against the variant.
  • Price Action: MRK shares closed 0.70% higher at $77.21 on the last check Thursday.
  • Photo by Thomas Breher from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.